TCA
NVCR icon

Transcend Capital Advisors’s NovoCure NVCR Stock Holding History

Transcend Capital Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$171K Buy
+15,676
New +$196K 0.01% 694

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Transcend Capital Advisors's NVCR Position: Q1 2026 in Review

Transcend Capital Advisors opened a new position in NovoCure (NVCR) in Q1 2026: 15,676 shares worth $171K. The stake represents 0.01% of the portfolio and ranks #694 among its holdings.

222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Transcend Capital Advisors held 15,676 shares of NovoCure worth $171K as of Q1 2026.
  • NovoCure was a new Transcend Capital Advisors position in Q1 2026.
  • NovoCure made up 0.01% of Transcend Capital Advisors's portfolio in Q1 2026, its #694 holding.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Transcend Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.